BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30244806)

  • 1. Biodistribution and Excretion of Intravenously Injected Mesoporous Silica Nanoparticles: Implications for Drug Delivery Efficiency and Safety.
    Lindén M
    Enzymes; 2018; 43():155-180. PubMed ID: 30244806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesoporous silica nanoparticles in medicine--recent advances.
    Mamaeva V; Sahlgren C; Lindén M
    Adv Drug Deliv Rev; 2013 May; 65(5):689-702. PubMed ID: 22921598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape.
    Li L; Liu T; Fu C; Tan L; Meng X; Liu H
    Nanomedicine; 2015 Nov; 11(8):1915-24. PubMed ID: 26238077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biosafety of mesoporous silica nanoparticles; towards clinical translation.
    Lérida-Viso A; Estepa-Fernández A; García-Fernández A; Martí-Centelles V; Martínez-Máñez R
    Adv Drug Deliv Rev; 2023 Oct; 201():115049. PubMed ID: 37573951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New insights towards mesoporous silica nanoparticles as a technological platform for chemotherapeutic drugs delivery.
    Sábio RM; Meneguin AB; Ribeiro TC; Silva RR; Chorilli M
    Int J Pharm; 2019 Jun; 564():379-409. PubMed ID: 31028801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomedical application of mesoporous silica nanoparticles as delivery systems: a biological safety perspective.
    Hosseinpour S; Walsh LJ; Xu C
    J Mater Chem B; 2020 Nov; 8(43):9863-9876. PubMed ID: 33047764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models.
    Le Hoang Doan T; Mai NXD; Matsumoto K; Tamanoi F
    Enzymes; 2018; 44():61-82. PubMed ID: 30360815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hierarchical mesoporous silica nanoparticles for tailorable drug release.
    Wu W; Ye C; Xiao H; Sun X; Qu W; Li X; Chen M; Li J
    Int J Pharm; 2016 Sep; 511(1):65-72. PubMed ID: 27374197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesoporous silica nanoparticles: facile surface functionalization and versatile biomedical applications in oncology.
    Huang R; Shen YW; Guan YY; Jiang YX; Wu Y; Rahman K; Zhang LJ; Liu HJ; Luan X
    Acta Biomater; 2020 Oct; 116():1-15. PubMed ID: 32911102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo.
    Huang X; Li L; Liu T; Hao N; Liu H; Chen D; Tang F
    ACS Nano; 2011 Jul; 5(7):5390-9. PubMed ID: 21634407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
    Zhang W; Liu M; Liu A; Zhai G
    Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesoporous silica nanoparticles in nanotechnology.
    Douroumis D; Onyesom I; Maniruzzaman M; Mitchell J
    Crit Rev Biotechnol; 2013 Sep; 33(3):229-45. PubMed ID: 22724458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bioimaging Applications of Mesoporous Silica Nanoparticles.
    Pratiwi FW; Kuo CW; Wu SH; Chen YP; Mou CY; Chen P
    Enzymes; 2018; 43():123-153. PubMed ID: 30244805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.
    Lin D; Cheng Q; Jiang Q; Huang Y; Yang Z; Han S; Zhao Y; Guo S; Liang Z; Dong A
    Nanoscale; 2013 May; 5(10):4291-301. PubMed ID: 23552843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation.
    He Q; Zhang Z; Gao F; Li Y; Shi J
    Small; 2011 Jan; 7(2):271-80. PubMed ID: 21213393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vivo Tracking of the Degradation of Mesoporous Silica through
    Bindini E; Ramirez MLA; Rios X; Cossío U; Simó C; Gomez-Vallejo V; Soler-Illia G; Llop J; Moya SE
    Small; 2021 Jul; 17(30):e2101519. PubMed ID: 34145769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics.
    Dogra P; Adolphi NL; Wang Z; Lin YS; Butler KS; Durfee PN; Croissant JG; Noureddine A; Coker EN; Bearer EL; Cristini V; Brinker CJ
    Nat Commun; 2018 Oct; 9(1):4551. PubMed ID: 30382084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluation of paclitaxel-loaded mesoporous silica nanoparticles with three pore sizes.
    Jia L; Shen J; Li Z; Zhang D; Zhang Q; Liu G; Zheng D; Tian X
    Int J Pharm; 2013 Mar; 445(1-2):12-9. PubMed ID: 23384728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
    She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
    Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of Thymoquinone-loaded mesoporous silica nanoparticles to different brain areas: In vivo study.
    Fahmy HM; Fathy MM; Abd-Elbadia RA; Elshemey WM
    Life Sci; 2019 Apr; 222():94-102. PubMed ID: 30826496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.